|
US6218160B1
(en)
*
|
1997-10-31 |
2001-04-17 |
Roche Diagnostics Corporation |
Site-specific conjugation of glycoproteins
|
|
KR20010024326A
(ko)
*
|
1998-07-29 |
2001-03-26 |
고토 기치 |
신규한 디아미노 화합물, 폴리암산, 폴리이미드, 당해폴리이미드 막으로부터 제조된 액정 배향막 및 당해배향막을 함유하는 액정 표시소자
|
|
US6706892B1
(en)
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
|
EP1889639A3
(en)
*
|
1999-09-07 |
2008-04-09 |
ConjuChem Biotechnologies Inc. |
Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents
|
|
WO2001017614A2
(en)
*
|
1999-09-07 |
2001-03-15 |
Conjuchem, Inc. |
Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
JP4414142B2
(ja)
|
2001-05-11 |
2010-02-10 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
特異的結合タンパク質およびその使用
|
|
NZ511705A
(en)
*
|
2001-05-14 |
2004-03-26 |
Horticulture & Food Res Inst |
Methods and rapid immunoassay device for detecting progesterone and other steroids
|
|
WO2002096910A1
(en)
*
|
2001-05-31 |
2002-12-05 |
Medarex, Inc. |
Cytotoxins, prodrugs, linkers and stabilizers useful therefor
|
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
|
US20050239688A1
(en)
*
|
2002-07-24 |
2005-10-27 |
Anne-Marie Fernandez |
Method for the synthesis of anthracycline-peptide conjugates
|
|
US20040047917A1
(en)
*
|
2002-09-06 |
2004-03-11 |
Stephen Wilson |
Drug delivery and targeting with vitamin B12 conjugates
|
|
US20040202666A1
(en)
*
|
2003-01-24 |
2004-10-14 |
Immunomedics, Inc. |
Anti-cancer anthracycline drug-antibody conjugates
|
|
AU2011236095B2
(en)
*
|
2003-01-24 |
2013-08-01 |
Immunomedics, Inc. |
Anthracycline-antibody conjugates
|
|
ATE472338T1
(de)
|
2003-02-20 |
2010-07-15 |
Seattle Genetics Inc |
Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
|
|
US7053191B2
(en)
*
|
2003-05-21 |
2006-05-30 |
Solux Corporation |
Method of preparing 4-R-substituted 4-demethoxydaunorubicin
|
|
EP1668424A4
(en)
*
|
2003-09-12 |
2009-11-25 |
Onkor Pharmaceuticals Inc |
MAGNETICALLY DETERMINABLE PARTICLES WITH MAGNETIC COMPONENTS AND BIOCOMPATIBLE POLYMERS FOR THE LOCAL DELIVERY OF BIOLOGICALLY ACTIVE ACTIVE SUBSTANCES
|
|
US7691962B2
(en)
*
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
|
WO2005112919A2
(en)
*
|
2004-05-19 |
2005-12-01 |
Medarex, Inc. |
Self-immolative linkers and drug conjugates
|
|
US7541330B2
(en)
*
|
2004-06-15 |
2009-06-02 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
|
WO2006015318A2
(en)
*
|
2004-07-30 |
2006-02-09 |
Biogen Idec Inc. |
Antibody conjugated to a drug moiety via a poptidic linker
|
|
JP2008521411A
(ja)
|
2004-11-30 |
2008-06-26 |
キュラジェン コーポレイション |
Ｇｐｎｍｂに対する抗体およびその使用
|
|
PL1851250T3
(pl)
*
|
2005-02-18 |
2012-10-31 |
Squibb & Sons Llc |
Ludzkie przeciwciało monoklonalne przeciwko antygenowi błony komórkowej komórek prostaty (PSMA)
|
|
ES2353212T3
(es)
*
|
2005-03-30 |
2011-02-28 |
Saladax Biomedical Inc. |
Inmunoensayo de doxorrubicina.
|
|
US7714016B2
(en)
*
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
|
NZ566982A
(en)
*
|
2005-09-26 |
2011-06-30 |
Medarex Inc |
Duocarmycin drug conjugates
|
|
ATE534629T1
(de)
|
2005-10-26 |
2011-12-15 |
Medarex Inc |
Verfahren und verbindungen zur herstellung von cc-1065-analoga
|
|
CA2627190A1
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
|
JP5230610B2
(ja)
|
2006-05-05 |
2013-07-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
二価ｓｍａｃ模倣物およびその使用
|
|
CA2699837C
(en)
|
2006-12-01 |
2017-06-13 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
|
CN104013956B
(zh)
|
2007-01-25 |
2018-12-18 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
|
AR065404A1
(es)
|
2007-02-21 |
2009-06-03 |
Medarex Inc |
Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
|
|
CA2680854C
(en)
|
2007-03-15 |
2017-02-14 |
Ludwig Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
|
CA2680237C
(en)
|
2007-03-27 |
2018-11-06 |
Sea Lane Biotechnologies, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
CN108424454B
(zh)
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
|
ES2629440T5
(es)
|
2007-10-04 |
2020-11-20 |
Zymogenetics Inc |
zB7H6 miembro de la familia B7 y composiciones y métodos relacionados
|
|
US8357785B2
(en)
*
|
2008-01-08 |
2013-01-22 |
Solux Corporation |
Method of aralkylation of 4′-hydroxyl group of anthracylins
|
|
MX2010007767A
(es)
|
2008-01-18 |
2010-08-09 |
Medimmune Llc |
Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
|
|
WO2010132604A2
(en)
|
2009-05-13 |
2010-11-18 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
|
AU2010270979B2
(en)
|
2009-06-22 |
2015-04-23 |
Medimmune, Llc |
Engineered Fc regions for site-specific conjugation
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
CN110054692A
(zh)
|
2009-10-23 |
2019-07-26 |
米伦纽姆医药公司 |
抗gcc抗体分子及其相关组合物和方法
|
|
CN102741290B
(zh)
|
2009-12-09 |
2015-04-22 |
国家健康和医学研究院 |
结合b7h6的单克隆抗体及其用途
|
|
TWI504410B
(zh)
|
2010-02-08 |
2015-10-21 |
Agensys Inc |
結合至１６１ｐ２ｆ１０ｂ蛋白之抗體藥物結合物（ａｄｃ）
|
|
CN105585630B
(zh)
|
2010-07-29 |
2020-09-15 |
Xencor公司 |
具有修改的等电点的抗体
|
|
AU2011312417B2
(en)
|
2010-09-29 |
2015-08-20 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
|
PT2648752T
(pt)
|
2010-12-06 |
2017-03-28 |
Seattle Genetics Inc |
Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
US8846882B2
(en)
|
2011-04-29 |
2014-09-30 |
Synbias Pharma Ag |
Method of producing 4-demethoxydaunorubicin
|
|
MX351069B
(es)
|
2011-05-27 |
2017-09-29 |
Glaxo Group Ltd |
Proteinas de union abcma (cd269/tnfrsf17).
|
|
US10300140B2
(en)
|
2011-07-28 |
2019-05-28 |
I2 Pharmaceuticals, Inc. |
Sur-binding proteins against ERBB3
|
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
WO2013055809A1
(en)
|
2011-10-10 |
2013-04-18 |
Xencor, Inc. |
A method for purifying antibodies
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
WO2013063702A1
(en)
|
2011-11-04 |
2013-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
CA2859744A1
(en)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Surrogate binding proteins
|
|
EP2794653B1
(en)
|
2011-12-23 |
2019-03-13 |
Pfizer Inc |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
WO2013109994A1
(en)
|
2012-01-20 |
2013-07-25 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
|
NZ628804A
(en)
|
2012-02-24 |
2017-08-25 |
Abbvie Stemcentrx Llc |
Dll3 modulators and methods of use
|
|
NZ741211A
(en)
|
2012-05-15 |
2019-09-27 |
Seattle Genetics Inc |
Self-stabilizing linker conjugates
|
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
AR092219A1
(es)
|
2012-08-23 |
2015-04-08 |
Seattle Genetics Inc |
Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7
|
|
JP6133431B2
(ja)
|
2012-11-24 |
2017-05-24 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． |
親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
DK2943511T3
(da)
|
2013-01-14 |
2019-10-21 |
Xencor Inc |
Nye heterodimeriske proteiner
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CN105209068A
(zh)
|
2013-02-07 |
2015-12-30 |
免疫医疗公司 |
用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
|
|
ME03394B
(me)
|
2013-02-22 |
2020-01-20 |
Medimmune Ltd |
Antidllз-antitelo-pbd konjugati i nihovа upotreba
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP3587448B1
(en)
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
|
WO2014194030A2
(en)
*
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
JP6510518B2
(ja)
|
2013-08-01 |
2019-05-08 |
アジェンシス，インコーポレイテッド |
Ｃｄ３７タンパク質に結合する抗体薬物結合体（ａｄｃ）
|
|
US9993566B2
(en)
|
2013-08-28 |
2018-06-12 |
Abbvie Stemcentrx Llc |
SEZ6 modulators and methods of use
|
|
BR112016004242A8
(pt)
|
2013-08-28 |
2018-06-12 |
Stemcentrx Inc |
Métodos para conjugação sítio-específica de anticorpos e composições
|
|
BR112016007402B1
(pt)
|
2013-10-11 |
2023-03-28 |
Oxford Biotherapeutics Ltd |
Anticorpo isolado, ou uma porção de ligação de antígeno deste, composição farmacêutica o compreendendo e seu uso, bem como ácido nucléico, vetor de expressão e método de produção de um anticorpo ou uma porção de ligação de antígeno deste
|
|
ES2960807T3
(es)
|
2013-10-11 |
2024-03-06 |
Us Health |
Anticuerpos contra TEM8 y su uso
|
|
KR102538993B1
(ko)
|
2013-10-15 |
2023-06-02 |
씨젠 인크. |
개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
|
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
WO2015077605A1
(en)
|
2013-11-25 |
2015-05-28 |
Seattle Genetics, Inc. |
Preparing antibodies from cho cell cultures for conjugation
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
SG11201605449YA
(en)
|
2014-01-10 |
2016-08-30 |
Birdie Biopharmaceuticals Inc |
Compounds and compositions for immunotherapy
|
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
|
|
PT3122757T
(pt)
|
2014-02-28 |
2023-11-03 |
Hangzhou Dac Biotech Co Ltd |
Ligantes carregados e as suas utilizações em conjugação
|
|
TW202330606A
(zh)
|
2014-03-21 |
2023-08-01 |
美商艾伯維有限公司 |
抗-egfr抗體及抗體藥物結合物
|
|
US10300070B2
(en)
|
2014-03-27 |
2019-05-28 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
|
BR112016022385A2
(pt)
|
2014-03-28 |
2018-06-19 |
Xencor, Inc |
anticorpos específicos que se ligam a cd38 e cd3
|
|
US20160060360A1
(en)
|
2014-07-24 |
2016-03-03 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
CN107428820B
(zh)
|
2014-11-19 |
2022-03-22 |
阿克松神经系统科学公司 |
在阿尔茨海默氏病中的人源化tau抗体
|
|
KR102689285B1
(ko)
|
2014-11-26 |
2024-07-31 |
젠코어 인코포레이티드 |
Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CN107406512A
(zh)
|
2014-11-26 |
2017-11-28 |
Xencor公司 |
结合cd3和cd38的异二聚体抗体
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
TW201702260A
(zh)
|
2015-03-05 |
2017-01-16 |
賽倫斯有限責任公司 |
環肽類似物及其共軛物
|
|
CN107614010A
(zh)
|
2015-03-09 |
2018-01-19 |
艾更斯司股份有限公司 |
结合至flt3蛋白的抗体药物偶联物(adc)
|
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
|
CA2989347A1
(en)
|
2015-06-12 |
2016-12-15 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
|
IL256295B2
(en)
|
2015-06-30 |
2023-11-01 |
Seagen Inc |
Anti-NTB-A antibodies and related compositions and methods
|
|
AU2015242213A1
(en)
|
2015-07-12 |
2018-03-08 |
Hangzhou Dac Biotech Co., Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
WO2017044803A1
(en)
|
2015-09-09 |
2017-03-16 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Service |
Expression vector delivery system and use thereof for inducing an immune response
|
|
WO2017062748A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
EP3660044A1
(en)
|
2015-10-09 |
2020-06-03 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
|
AU2016365742A1
(en)
|
2015-12-07 |
2018-06-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
EP3419655A1
(en)
|
2016-02-27 |
2019-01-02 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Peptide vaccines comprising self-assembling polymer nanoparticles
|
|
SMT202100416T1
(it)
|
2016-03-02 |
2021-09-14 |
Eisai R&D Man Co Ltd |
Coniugati anticorpo-farmaco a base di eribulina e metodi di uso
|
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
|
EP3433278A4
(en)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
|
|
CA3021098A1
(en)
|
2016-04-21 |
2017-10-26 |
Abbvie Stemcentrx Llc |
Novel anti-bmpr1b antibodies and methods of use
|
|
US11016085B2
(en)
|
2016-04-25 |
2021-05-25 |
The Johns Hopkins University |
ZNT8 assays for drug development and pharmaceutical compositions
|
|
JP2019524651A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗ｃｄ９８抗体及び抗体薬物コンジュゲート
|
|
WO2017214339A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
|
CN109963870B
(zh)
|
2016-06-08 |
2023-07-28 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
|
CA3027044A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
|
CN109562168A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
|
US10787518B2
(en)
|
2016-06-14 |
2020-09-29 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
BR112019001945A2
(pt)
|
2016-08-09 |
2019-05-07 |
Seattle Genetics, Inc. |
composição de conjugado de fármaco aglutinante, formulação farmaceuticamente aceitável, métodos para tratar uma doença ou afecção hiperproliferativa, para inibir a multiplicação de uma célula tumoral ou célula cancerígena e para preparar uma composição de conjugado de fármaco aglutinado, e, composto
|
|
EP4282969A3
(en)
|
2016-09-02 |
2024-01-31 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
|
WO2018045245A1
(en)
|
2016-09-02 |
2018-03-08 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
|
SG11201903302UA
(en)
|
2016-10-14 |
2019-05-30 |
Xencor Inc |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
|
KR20220147720A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
WO2018112334A1
(en)
|
2016-12-16 |
2018-06-21 |
Bluefin Biomedicine, Inc. |
Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
|
|
JP6706394B1
(ja)
|
2017-01-09 |
2020-06-03 |
レンティジェン・テクノロジー・インコーポレイテッドＬｅｎｔｉｇｅｎ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． |
抗メソセリン免疫療法によりがんを処置するための組成物および方法
|
|
EP3589654A1
(en)
|
2017-03-02 |
2020-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
|
US10426797B2
(en)
|
2017-03-24 |
2019-10-01 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD33 immunotherapy
|
|
JP7527787B2
(ja)
|
2017-03-24 |
2024-08-05 |
シージェン インコーポレイテッド |
グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
|
|
AU2018250226B2
(en)
|
2017-04-04 |
2025-04-24 |
Barinthus Biotherapeutics North America, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
|
CN110730908B
(zh)
|
2017-04-07 |
2025-01-21 |
朱诺治疗学股份有限公司 |
表达前列腺特异性膜抗原（psma）或其修饰形式的工程化细胞及相关方法
|
|
EP3612567B1
(en)
|
2017-04-19 |
2024-09-11 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
|
AU2018259856B2
(en)
|
2017-04-28 |
2025-05-01 |
Ajinomoto Co., Inc. |
Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
|
|
CN118994394A
(zh)
|
2017-06-12 |
2024-11-22 |
蓝鳍生物医药公司 |
抗-il1rap抗体和抗体药物缀合物
|
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
|
US10442867B2
(en)
|
2017-07-31 |
2019-10-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
|
TW201919712A
(zh)
|
2017-08-10 |
2019-06-01 |
法商塞勒尼斯醫療控股公司 |
運送子(cargomers)
|
|
EP3681903B1
(en)
|
2017-09-15 |
2023-07-19 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19 immunotherapy
|
|
JP7275118B2
(ja)
|
2017-10-16 |
2023-05-17 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ２２免疫療法によってがんを処置するための組成物および方法
|
|
CN120789287A
(zh)
|
2017-10-23 |
2025-10-17 |
马布林克生物科学公司 |
包含单分子量聚肌氨酸的配体-药物-缀合物
|
|
US10386338B2
(en)
|
2017-10-30 |
2019-08-20 |
Cynthia Rena Wright |
DNA/RNA PEMS microcantilever probe for detection of viral infection and detection of genetic variants
|
|
JP7448903B2
(ja)
|
2017-11-03 |
2024-03-13 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｒｏｒ１免疫療法によってがんを処置するための組成物および方法
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
BR112020010662A2
(pt)
|
2017-11-29 |
2020-11-10 |
Magenta Therapeutics, Inc. |
composições e métodos para a depleção de células cd5+
|
|
BR112020010937A2
(pt)
|
2017-12-01 |
2020-11-17 |
Seattle Genetics, Inc. |
anticorpos anti-liv1 humanizados para o tratamento de câncer de mama
|
|
CA3083946A1
(en)
|
2017-12-01 |
2019-06-06 |
Seattle Genetics, Inc. |
Cd47 antibodies and uses thereof for treating cancer
|
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
JP7377802B2
(ja)
|
2017-12-20 |
2023-11-10 |
レンティジェン・テクノロジー・インコーポレイテッド |
免疫療法を用いてｈｉｖ／ａｉｄｓを処置するための組成物および方法
|
|
WO2019183131A1
(en)
|
2018-03-19 |
2019-09-26 |
Bioventures, Llc |
Periostin antibodies and methods of using the same
|
|
WO2019180150A1
(en)
|
2018-03-22 |
2019-09-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
|
KR20200135841A
(ko)
|
2018-03-23 |
2020-12-03 |
시애틀 지네틱스, 인크. |
고형 종양을 치료하기 위한 튜불린 교란제들을 포함하는 항체 약물 접합체들의 용도
|
|
RU2020135052A
(ru)
|
2018-03-28 |
2022-04-29 |
Аксон Ньюросайенс Се |
Способы выявления и лечения болезни альцгеймера на основе антител
|
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
|
|
CN112867734A
(zh)
|
2018-04-18 |
2021-05-28 |
Xencor股份有限公司 |
包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
|
|
WO2019226828A2
(en)
|
2018-05-22 |
2019-11-28 |
Avidea Technologies, Inc. |
Improved methods of manufacturing peptide-based vaccines
|
|
IL316090A
(en)
|
2018-06-01 |
2024-12-01 |
Eisai R&D Man Co Ltd |
Antibody-drug conjugates of splicing modulators and methods of use
|
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
|
KR20210020901A
(ko)
|
2018-06-14 |
2021-02-24 |
아지노모토 가부시키가이샤 |
항체에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염
|
|
KR102880460B1
(ko)
|
2018-06-14 |
2025-11-06 |
아지노모토 가부시키가이샤 |
항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염
|
|
BR112020026724A2
(pt)
|
2018-07-02 |
2021-03-30 |
Amgen Inc. |
Proteína de ligação ao antígeno anti-steap1
|
|
JP2021532116A
(ja)
|
2018-07-23 |
2021-11-25 |
マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. |
同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
|
|
CN113166241B
(zh)
|
2018-08-16 |
2025-02-25 |
约翰霍普金斯大学 |
人类znt8抗体
|
|
CA3113058A1
(en)
|
2018-09-20 |
2020-03-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd123 immunotherapy
|
|
CN113286607B
(zh)
|
2018-09-26 |
2024-07-12 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
|
US20210393523A1
(en)
|
2018-10-03 |
2021-12-23 |
Avldea Technologies, Inc. |
Aromatic ring substituted amphiphilic polymers as drug delivery systems
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
JPWO2020090979A1
(ja)
|
2018-10-31 |
2021-09-24 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
|
AU2019387377A1
(en)
|
2018-11-30 |
2021-06-17 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD38 immunotherapy
|
|
US12257340B2
(en)
|
2018-12-03 |
2025-03-25 |
Agensys, Inc. |
Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
|
|
PH12021551389A1
(en)
|
2018-12-13 |
2022-05-16 |
Eisai R&D Man Co Ltd |
Herboxidiene antibody-drug conjugates and methods of use
|
|
CA3122316A1
(en)
*
|
2018-12-21 |
2020-06-25 |
Seagen Inc. |
Adcs with thiol multiplex linkers
|
|
BR112021015477A2
(pt)
|
2019-02-05 |
2021-12-28 |
Seagen Inc |
Anticorpos anti-cd228 e conjugados anticorpo-fármaco
|
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
JP7650809B2
(ja)
|
2019-03-06 |
2025-03-25 |
レンティジェン・テクノロジー・インコーポレイテッド |
自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法
|
|
SI3941946T1
(sl)
|
2019-03-20 |
2025-09-30 |
The Regents Of The University Of California |
Protitelesa proti klavdinu-6 in konjugati zdravil
|
|
CA3134056A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
|
JP2022529183A
(ja)
|
2019-04-17 |
2022-06-17 |
アヴィディア テクノロジーズ， インコーポレイテッド |
リガンド提示および／または薬物送達のためのスターポリマーを製造する組成物および方法
|
|
KR20220003572A
(ko)
|
2019-04-24 |
2022-01-10 |
하이델베르크 파마 리서치 게엠베하 |
아마톡신 항체-약물 결합체 및 이의 용도
|
|
EP3976653A1
(en)
|
2019-05-30 |
2022-04-06 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
|
WO2020247574A1
(en)
|
2019-06-05 |
2020-12-10 |
Seattle Genetics, Inc. |
Methods of purifying masked antibodies
|
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
|
EP3994173A1
(en)
|
2019-07-02 |
2022-05-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
|
MX2022000853A
(es)
|
2019-07-22 |
2022-03-17 |
Seagen Inc |
Anticuerpos anti-liv1 humanizados para el tratamiento de cancer.
|
|
US12366570B2
(en)
|
2019-10-01 |
2025-07-22 |
The Johns Hopkins University |
Cell-based ZNT8 assay
|
|
MX2022003935A
(es)
|
2019-10-04 |
2022-04-25 |
Tae Life Sciences Llc |
Composiciones de anticuerpo que comprenden mutaciones fc y propiedades de conjugacion especificas del sitio.
|
|
BR112022005114A2
(pt)
|
2019-10-04 |
2022-06-21 |
Seagen Inc |
Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
|
|
EP3812008A1
(en)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-competitive antagonist antibody
|
|
EP4072682A1
(en)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antibodies having specificity to her4 and uses thereof
|
|
JP2023509760A
(ja)
|
2020-01-08 |
2023-03-09 |
シンシス セラピューティクス，インコーポレイテッド |
Ａｌｋ５阻害剤複合体およびその使用
|
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
|
CA3180683A1
(en)
|
2020-05-12 |
2021-11-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
MX2022015374A
(es)
|
2020-06-05 |
2023-01-16 |
Eisai R&D Man Co Ltd |
Conjugados de anticuerpo anti antigeno de maduracion de linfocitos b (bcma)-farmaco y metodos de uso.
|
|
EP4163294A4
(en)
|
2020-06-09 |
2024-07-24 |
Ajinomoto Co., Inc. |
MODIFIED FERRITIN AND METHOD FOR PRODUCING SAME
|
|
WO2021262723A1
(en)
|
2020-06-22 |
2021-12-30 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
|
EP4192871A1
(en)
|
2020-08-04 |
2023-06-14 |
Seagen Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
|
EP4216927A1
(en)
|
2020-09-22 |
2023-08-02 |
Vaccitech North America, Inc. |
Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
|
|
JP2023543026A
(ja)
|
2020-09-28 |
2023-10-12 |
シージェン インコーポレイテッド |
がんの処置のためのヒト化抗ｌｉｖ１抗体
|
|
CA3197168A1
(en)
|
2020-10-01 |
2022-04-07 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
|
CA3195623A1
(en)
|
2020-10-19 |
2022-04-28 |
Geoffrey Martin Lynn |
Star polymer drug conjugates
|
|
US20230303604A1
(en)
|
2020-10-20 |
2023-09-28 |
Institut Curie |
Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
|
|
WO2022099026A1
(en)
|
2020-11-05 |
2022-05-12 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
|
CN116761819A
(zh)
|
2021-01-18 |
2023-09-15 |
味之素株式会社 |
化合物或其盐、以及由它们得到的抗体
|
|
CA3208296A1
(en)
|
2021-01-18 |
2022-07-21 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody obtained by using the same
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
JP2024506381A
(ja)
|
2021-02-16 |
2024-02-13 |
ヴァクシテック ノース アメリカ， インコーポレイテッド |
両親媒性ペプチドに基づく自己集合ナノ粒子
|
|
WO2022192403A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
KR20230154853A
(ko)
|
2021-03-11 |
2023-11-09 |
아지노모토 가부시키가이샤 |
화합물 또는 이의 염, 및 이들에 의해 얻어지는 항체
|
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
|
WO2022196675A1
(ja)
|
2021-03-16 |
2022-09-22 |
味の素株式会社 |
複合体またはその塩、およびその製造方法
|
|
US12036286B2
(en)
|
2021-03-18 |
2024-07-16 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
|
MX2023011031A
(es)
|
2021-03-19 |
2023-12-14 |
Heidelberg Pharma Res Gmbh |
Conjugados de amatoxina y anticuerpo especificos de linfocitos b.
|
|
MX2023011507A
(es)
|
2021-03-30 |
2023-10-04 |
Legochem Biosciences Inc |
Conjugado anticuerpo- farmaco que incluye un anticuerpo contra la cldn18.2 humana y uso del mismo.
|
|
CA3215049A1
(en)
|
2021-04-10 |
2022-10-13 |
Baiteng ZHAO |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
CN117479834A
(zh)
|
2021-04-15 |
2024-01-30 |
阿比奥尼克斯制药公司 |
基于脂质结合蛋白的复合物在器官保存溶液中的用途
|
|
JP7742892B2
(ja)
|
2021-04-23 |
2025-09-22 |
ジェンマブ エー／エス |
抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
US20240352080A1
(en)
|
2021-07-14 |
2024-10-24 |
Seagen Inc. |
Antibody Masking Domains
|
|
JP2024534047A
(ja)
|
2021-08-20 |
2024-09-18 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
膵臓ベータ細胞の特定のバイオマーカーに対する細胞表面抗体
|
|
US20240376200A1
(en)
|
2021-09-24 |
2024-11-14 |
Seagen Inc. |
Improved Antibody Masking Domains
|
|
EP4410830A1
(en)
|
2021-09-30 |
2024-08-07 |
Ajinomoto Co., Inc. |
Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound or salts thereof to be used in producing conjugate or salt thereof
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
US20250073346A1
(en)
|
2021-11-18 |
2025-03-06 |
Oxford Bio Therapeutics Ltd |
Pharmaceutical combinations
|
|
EP4433096A1
(en)
|
2021-11-19 |
2024-09-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
|
EP4489859A1
(en)
|
2022-03-09 |
2025-01-15 |
Astrazeneca AB |
Binding molecules against fr alpha
|
|
IL314452A
(en)
|
2022-03-11 |
2024-09-01 |
Astrazeneca Ab |
A scoring method for an anti-frα antibody-drug conjugate therapy
|
|
EP4504150A1
(en)
|
2022-04-06 |
2025-02-12 |
Abionyx Pharma SA |
Methods for treating eye diseases using lipid binding protein-based complexes
|
|
EP4504270A1
(en)
|
2022-04-07 |
2025-02-12 |
Heidelberg Pharma Research GmbH |
Methods of improving the therapeutic index of amatoxin-antibody conjugates
|
|
EP4562043A2
(en)
|
2022-07-28 |
2025-06-04 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
|
JP2025529917A
(ja)
|
2022-08-26 |
2025-09-09 |
レンティジェン・テクノロジー・インコーポレイテッド |
完全ヒト抗ｃｄ２０／ｃｄ１９免疫療法によりがんを処置するための組成物および方法
|
|
EP4584291A1
(en)
|
2022-09-08 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
|
CN120282982A
(zh)
|
2022-09-21 |
2025-07-08 |
思进公司 |
结合cd228的抗体
|
|
EP4608455A1
(en)
|
2022-10-25 |
2025-09-03 |
Barinthus Biotherapeutics North America, Inc. |
Self-assembling nanoparticles
|
|
AU2023367778A1
(en)
|
2022-10-25 |
2025-05-01 |
Barinthus Biotherapeutics North America, Inc. |
Combination treatment regimes for treating cancer
|
|
AU2023374571A1
(en)
|
2022-11-01 |
2025-04-03 |
Heidelberg Pharma Research Gmbh |
Anti-gucy2c antibody and uses thereof
|
|
WO2024097816A1
(en)
|
2022-11-03 |
2024-05-10 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
|
EP4382120A1
(en)
|
2022-12-05 |
2024-06-12 |
Institut Regional du Cancer de Montpellier |
Anti-slc1a4 monoclonal antibodies and uses thereof
|
|
WO2024121632A1
(en)
|
2022-12-09 |
2024-06-13 |
Crispr Therapeutics Ag |
Use of anti-cd117 antibody drug conjugate (adc)
|
|
KR20250148670A
(ko)
|
2023-02-16 |
2025-10-14 |
아스트라제네카 아베 |
치료용 결합 분자를 사용한 암 치료를 위한 병용 요법
|
|
KR20250152101A
(ko)
|
2023-03-13 |
2025-10-22 |
하이델베르크 파마 리서치 게엠베하 |
암 치료에의 사용을 위한 피하 투여 항체-약물 접합체
|
|
KR20250172615A
(ko)
|
2023-04-04 |
2025-12-09 |
아지노모토 가부시키가이샤 |
항체 및 기능성 물질의 컨쥬게이트, 항체 유도체 및 화합물, 또는 그것들의 염
|
|
CN121039143A
(zh)
|
2023-04-05 |
2025-11-28 |
味之素株式会社 |
抗体和功能性物质的缀合物或其盐、以及具有硫醇基的抗体中间体或其盐
|
|
WO2024230756A1
(zh)
|
2023-05-09 |
2024-11-14 |
上海复宏汉霖生物技术股份有限公司 |
一种抗表皮生长因子受体(egfr)抗体-药物偶联物及其应用
|
|
AU2024273407A1
(en)
|
2023-05-17 |
2025-12-04 |
Centre National De La Recherche Scientifique |
Anti-cathepsin-d antibodies
|
|
WO2024258743A1
(en)
|
2023-06-13 |
2024-12-19 |
Adcentrx Therapeutics, Inc. |
Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
|
|
WO2024258967A1
(en)
|
2023-06-13 |
2024-12-19 |
Synthis Therapeutics, Inc. |
Anti-cd5 antibodies and their uses
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
WO2025021928A1
(en)
|
2023-07-25 |
2025-01-30 |
Merck Patent Gmbh |
Iduronidase-cleavable compounds
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|
|
EP4512427A1
(en)
|
2023-08-25 |
2025-02-26 |
Mablink Bioscience |
Antibody-drug conjugates based on molecular glue degraders and uses thereof
|
|
TW202535954A
(zh)
|
2023-09-26 |
2025-09-16 |
丹麥商珍美寶股份有限公司 |
Ｐｔｋ７結合劑、其共軛物及使用彼等之方法
|
|
WO2025109097A2
(en)
|
2023-11-24 |
2025-05-30 |
Heidelberg Pharma Research Gmbh |
Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereof
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
US20250296992A1
(en)
|
2024-01-10 |
2025-09-25 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025163468A1
(en)
|
2024-01-30 |
2025-08-07 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
US20250295801A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody drug conjugates, and uses thereof
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025248097A2
(en)
|
2024-05-31 |
2025-12-04 |
Gamamabs Pharma |
Humanized anti-human her3 antibodies and uses thereof
|